Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhangyanming tablets plus hypoglycemic therapy for metabolic cataract
ChiCTR2300070388Phase 4Not yet recruiting
- Sponsor
- Guangzhou First People's Hospital
- Start
- Apr 2023
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of zhangyanming in metabolic cataract and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Guangzhou First People's Hospital. Primary endpoint: Cataract treatment effective. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
zhangyanming
03
Conditions
metabolic cataracttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2300070388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070388.